Anshul Rathi’s Post

Another feather in the cap ! 👩⚕️ Healthcare is a sensitive and personal domain for most people. They tend to trust traditional or familiar sources of healthcare more than new or innovative ones. Therefore, healthcare startups have to overcome the challenge of creating awareness and trust among their potential customers. They also have to deal with the low penetration and adoption of digital technologies in the healthcare sector. 💡 Bringing innovation and making disruption in healthcare require more credibility through various clinical trials, peer reviewed journals and others. Innovation is need of hour to make service as affordable as we can. The cost of quality healthcare is escalating at a fast pace, making it increasingly unaffordable for individuals and families. This trend poses a significant challenge as it hinders access to essential medical services and raises concerns about the affordability and sustainability of providing high-quality healthcare to all segments of the population. 📑 We are really thankful to all doctors and authors for conducting the evaluation and applied for the publication , Dr. A. M. Amrutha, Dr. Bhagyalaxmi Sidenur & Dr. Nagendra Gowda M.R Department of Community Medicine, Basaveshwara Medical College & Hospital, Chitradurga, Karnataka, India   Dr. Balu P S, C-DART, Basaveshwara Medical College & Hospital, Chitradurga, India   Dr.Savitha S.V ,SJM Institute of Nursing, Chitradurga, India   Dr. Harshavardhan Rajagopal, MBBS, American Hospital Dubai, Dubai, UAE 📚 Publication link: https://lnkd.in/gp5DdyGD EzeRx Department Of Biotechnology, Government Of india Department of Science and Technology MeitY Startup Hub Indian Oil Corp Limited Ministry of Health and Family Welfare, Government of India PATH Bill & Melinda Gates Foundation Clinton Foundation UNICEF T-Hub KIIT-Technology Business Incubator World Health Organization Dr SANDEEP SHARMA Chaitali Roy Sudip Roy Chowdhury Shromon Ghosh Dipti Sundar Mohanty Mrutyunjay Suar, PhD Komal Agarwal Sarada Samantaray CA CS Abinash Parida SANTI RANJAN KARAR Neeraj Jain Nalin Sharma Tata Trusts Tata Steel Foundation Reliance Foundation Adani Foundation CARE CARE India swarup guha ray Arnab Bhattacharya Pritha Mukhopadhay Debasis Basu Kalyan Kar #Publication #Review #Impact #AtmanirbharBharat #MakeInIndia

AI-driven solutions and collaborations with startups, PPPs, and private players hold the key to transforming rural healthcare in India by addressing infrastructure gaps, enhancing diagnostics, and improving accessibility. Head to our website to read more: https://lnkd.in/gwHcSRy9 Heartnet India ARINDAM SEN #indiamedtoday #heartnet #healthcare #healthcarenews #healthcareupdates

Recent medical reports suggest that the burden of kidney failure is increasing in India, with 210,000 new cases being diagnosed each year. It begs the question- 𝙒𝙝𝙮 𝙝𝙖𝙨 𝘾𝙝𝙧𝙤𝙣𝙞𝙘 𝙆𝙞𝙙𝙣𝙚𝙮 𝘿𝙞𝙨𝙚𝙖𝙨𝙚 (𝘾𝙆𝘿) 𝙚𝙢𝙚𝙧𝙜𝙚𝙙 𝙖𝙨 𝙖 𝙢𝙖𝙟𝙤𝙧 𝙥𝙪𝙗𝙡𝙞𝙘 𝙝𝙚𝙖𝙡𝙩𝙝 𝙘𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚 𝙞𝙣 𝙄𝙣𝙙𝙞𝙖 𝙖𝙣𝙙 𝙖𝙘𝙧𝙤𝙨𝙨 𝙩𝙝𝙚 𝙂𝙡𝙤𝙗𝙚? Our sustained engagement with various stakeholders in the healthcare industry in India over the last 6-7 years has led us to delve deeper in understanding a fundamental question: 𝙒𝙝𝙚𝙩𝙝𝙚𝙧 𝙡𝙖𝙬, 𝙧𝙚𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙖𝙣𝙙 𝙥𝙤𝙡𝙞𝙘𝙮 𝙘𝙤𝙣𝙘𝙚𝙧𝙣𝙞𝙣𝙜 𝙩𝙝𝙚 𝙚𝙨𝙩𝙖𝙗𝙡𝙞𝙨𝙝𝙢𝙚𝙣𝙩, 𝙤𝙥𝙚𝙧𝙖𝙩𝙞𝙤𝙣 𝙖𝙣𝙙 𝙢𝙖𝙣𝙖𝙜𝙚𝙢𝙚𝙣𝙩 𝙤𝙛 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙚𝙨𝙩𝙖𝙗𝙡𝙞𝙨𝙝𝙢𝙚𝙣𝙩𝙨, 𝙨𝙥𝙚𝙘𝙞𝙛𝙞𝙘𝙖𝙡𝙡𝙮 𝙙𝙞𝙖𝙡𝙮𝙨𝙞𝙨 𝙘𝙚𝙣𝙩𝙧𝙚𝙨, 𝙞𝙣 𝙄𝙣𝙙𝙞𝙖, 𝙖𝙘𝙩𝙨 𝙖𝙨 𝙖𝙣 𝙚𝙣𝙖𝙗𝙡𝙚𝙧 𝙊𝙍 𝙖𝙣 𝙤𝙗𝙨𝙩𝙖𝙘𝙡𝙚 𝙞𝙣 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙞𝙣𝙜 𝙩𝙞𝙢𝙚𝙡𝙮 𝙖𝙣𝙙 𝙘𝙤𝙨𝙩-𝙚𝙛𝙛𝙞𝙘𝙞𝙚𝙣𝙩 𝙥𝙖𝙩𝙞𝙚𝙣𝙩-𝙘𝙚𝙣𝙩𝙧𝙞𝙘 𝙣𝙚𝙥𝙝𝙧𝙤𝙘𝙖𝙧𝙚? Over the course of the next few weeks, follow our team, led by Mahit Anand, Sumedh Bhargav Niyogi and Anuragh Karat, as they share bite sized content, showcasing research and analysis on: ⭕ The current regulatory framework for renal care in India, and our recommendations to the legal structure around the regulations governing: (i) manufacture and import of dialysis machines; (ii) establishment of dialysis centres; (iii) procurement of dialysis machines; (iv) kidney transplantation; and (v) qualifications and training of medical care providers etc. ⭕ How does law, policy and regulation in India stack up in comparison to the frameworks in other advanced countries? From resources available in the public domain, we were able to analyze frameworks in Singapore, USA (California) and Australia in greater detail. ⭕ To what extent have the initiatives undertaken by the Government - such as the Pradhan Mantri National Dialysis Program (PMNDP) and the National Health Program (NHP) proven to be effective in improving access to quality nephrocare through different models of operation. ⭕ What is the role being played by the private sector - nephrocare startups, healthcare business incubators and accelerators and venture capital firms, to turbocharge access to quality nephrocare in India? STAY TUNED!! Amrut Joshi Samheeta Rao Mahit Anand Saket Rachakonda Dia S. Saurav Gurjer Sumedh Bhargav Niyogi #nephrocare #renalcare #kidney #PMNDP #NHP #dialysis #dialysiscentres #hemodialysis #peritonealdialysis #kidneytransplant #healthcare #law #policy #regulations #incubators #venturecapital #gamechangerlaw

I had written this article about healthcare in India, compared to the (so called) developed countries. Offlate I have come to a realisation that most of them are resource constraint countries as they cannot deliver the required care in time. India is far ahead in this regard at every price point and we have more capacity. Indian doctors are willing to work and care. We have better access to doctors and technology. Click to Read: https://lnkd.in/gapeGJcC

I had written this article about healthcare in India, compared to the (so called) developed countries. Offlate I have come to a realisation that most of them are resource constraint countries as they cannot deliver the required care in time. India is far ahead in this regard at every price point and we have more capacity. Indian doctors are willing to work and care. We have better access to doctors and technology. Click to Read: https://lnkd.in/gapeGJcC

I had written this article about healthcare in India, compared to the (so called) developed countries. Offlate I have come to a realisation that most of them are resource constraint countries as they cannot deliver the required care in time. India is far ahead in this regard at every price point and we have more capacity. Indian doctors are willing to work and care. We have better access to doctors and technology. Click to Read: https://lnkd.in/gN-sz6-j

India is at a crossroad for #healthcare delivery. Proud to be. part of this ecosystem. This is a wonderful article by a senior Dr Sandeep Nayak from my #almamater Kasturba Medical College, Mangalore. This is also a time to pause for perspective. While our expertise and competency is today recognised by peers and patients from across the world , at the other end 1.There is a constant lens on every small decision through consumer activism. ( yes I call it that as many involved in the process are not aware of the nuances of healthcare but are able to deliver judgements), 2.Scrutiny from civil bodies including supreme court on tariff, which may risk many hospitals to become untenable (there is no logical costing of services done), and 3.Populist schemes with inadequate funding make it very difficult to provide care. Insurance premiums are up but payouts to hospitals are the same for years. We need some method to this madness. This is important to ensure that patients continue to be able to access healthcare close to home and we imitate the insurance driven like the west .. but adapt it for India & Bharath. Is there a dialogue possible among stakeholders to let the system be or make it a win-win ?

Budget 2024 Health Sector Highlights Healthcare Initiatives Emphasis on tackling non-communicable diseases and healthcare research. Customs duty exemptions for cancer treatment drugs: Trastuzumab Deruxtecan, Osimertinib, and Durvalumab. Establishment of the Powering Innovation, Medical Research & Development (R&D) Anusandhan National Research Fund with Rs 1 lakh crore for private sector-driven research and innovation. Investment in cybersecurity and AI research, including healthcare, with over Rs 1,550 crore allocated. Financial Allocations Health Ministry allocated Rs 90,958.63 crore, a 12.9% increase from the previous budget. Department of Health and Family Welfare receives Rs 87,656.90 crore. Department of Health Research receives Rs 3,301.73 crore. Reduced funding for PM Swasthya Suraksha Yojana from Rs 3,365 crore to Rs 2,200 crore. Economic and Industrial Developments Proposed changes to basic customs duty for X-ray tubes and flat panel detectors in medical X-ray machines to support domestic capacity expansion. Sanctioning of 12 new industrial parks and 'plug and play' parks near 100 cities for pharma and medtech industries to boost local production and the ‘Make in India’ initiative. These parks will attract investments, stimulate innovation, and create job opportunities. Educational and Regional Development Education loans of Rs 10 lakh for higher studies in India to support students studying abroad, reducing brain drain. 3% reduction in education loan interest to alleviate financial stress for students. Government’s plan to offer 1 crore youth internships over five years to enhance employability and practical skills in healthcare. New airports and medical facilities for Bihar to enhance regional healthcare and development, improving healthcare accessibility and infrastructure. Analysis Rs 90,958 crore allocation is a 12.9% increase, insufficient to bridge the healthcare demand-supply gap. Budget focuses on youth employment, MSMEs, agriculture, and infrastructure but lacks emphasis on healthcare as a pillar of development.

🇮🇳INDIA CALLING DANISH HEALTHTECH AND MEDTECH INNOVATORS🇮🇳 🚀 Join us for a unique webinar 29 April to explore the vast opportunities in the Indian Healthtech and Medtech market! 🇮🇳💡 🏥 Meet Marengo Asia Hospitals, an innovative private hospital chain eager to embrace cutting-edge technologies - particularly within the fields of Cardiology, Neurology, Oncology, Nephrology, and Surgeries. Why should 🇩🇰 Danish Healthcare, Medical Devices, and Life Sciences stakeholders join? 🔍 Discover the potential synergy between Denmark's pioneering solutions and India's booming market, where 70%-75% of medical devices are imported. 💰 Dive into the lucrative Indian market, estimated at USD 11 billion and growing by 18-20% annually, with 100+ large private hospitals and a thriving ecosystem in cities like Hyderabad and Bangalore. 🌐 Explore how Danish companies can revolutionize Indian healthcare, driven by rising healthcare spending, government initiatives, and a growing demand for advanced medical technologies. How can we assist Danish stakeholders in the Indian market? 🔍 Opportunity Identification: Identify gaps and opportunities to enhance patient care and streamline healthcare processes. 📚 Knowledge Exchange: Engage in virtual sessions and workshops to share insights on regulatory pathways, digital adoption, and best practices. 🌍 Market Visit: Join us for future market visits to meet key stakeholders and explore partnership opportunities firsthand. 🚀 Market Expansion: Seize the opportunity to introduce Danish products and services to the Indian market through strategic alliances and targeted market penetration. Don't miss out on this chance to be part of India's healthcare revolution! Reach out to me today to learn more about how to unlock the potential for innovation and growth. #HealthTech #MedTech #IndiaOpportunity 🌟 Innovation Centre Denmark Bangalore The Trade Council Danish Life Science Cluster Health Tech Hub Copenhagen Erhvervshus Hovedstaden Joel Stafford Oded Yair Menuhin Nils Robenhagen Michael Lejrskov

Next Steps of Indian Pharma Industry: Affordable Meds with quality and greater accessibility especially for rural population, Addressing AMR, significant investment in R&D, pharma and biotech startups, AI-based pharma IT hubs and India for World–a road towards Viksit Bharat. Well, it's important to note what @Rajeev Juneja, VC and MD, MANKIND PHARMA LTD Pharma highlighted, "Every fourth tablet consumed globally is made in India. We have come a long way in producing affordable, high-quality medicines for the world." Other critical view shared by Madhukar Kumar Bhagat, Joint Secretary, Union Ministry of Health and Family Welfare, Government of India, Dr. Shefali Misra, Group Vice President of Public Policy & Government Affairs at Biocon Group,  Dr. Sangeeta Sharma, Professor and Head of Neuropsychopharmacology at the Institute of Human Behaviour & Allied Sciences IHBAS Neurology, Genessa Giorgi, Health Attaché at the U.S. Embassy at the 21st Indo-US Economic Summit. #IndianPharmaIndusry #Pharma_Industry #AI_Pharma_IT_Hubs #Pharma_Startups #Biotech_Startups Read my story here: